DOXYCYCLINE

DOXYCYCLINE- doxycycline capsule
Aidarex Pharmaceuticals LLC

Rx only

To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

DESCRIPTION

Doxycycline is a broad-spectrum antibacterial synthetically derived from oxytetracycline. Doxycycline Capsules USP, 100 mg, 75 mg, and 50 mg capsules contain doxycycline monohydrate equivalent to 100 mg, 75 mg, or 50 mg of doxycycline for oral administration. The chemical designation of the light-yellow crystalline powder is alpha-6-deoxy-5-oxytetracycline.

Structural formula:

Doxycycline Monohydrate
(click image for full-size original)

Doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form.

Inert ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose and sodium starch glycolate. Hard gelatin capsule contains black iron oxide, gelatin, red iron oxide, titanium dioxide and yellow iron oxide. The capsules are printed with edible ink containing black iron oxide, potassium hydroxide, propylene glycol, shellac and titanium dioxide.

CLINICAL PHARMACOLOGY

Tetracyclines are readily absorbed and are bound to plasma proteins in varying degrees. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form. Doxycycline is virtually completely absorbed after oral administration.

Following a 200 mg dose of doxycycline monohydrate, 24 normal adult volunteers averaged the following serum concentration values:

Time ( hr ): 0.5 1.0 1.5 2.0 3.0 4.0 8.0 12.0 24.0 48.0 72.0
Conc . 1.02 2.26 2.67 3.01 3.16 3.03 2.03 1.62 0.95 0.37 0.15 (mcg/mL)
Average Observed Values
Maximum Concentration 3.61 mcg/mL (± 0.9 sd)
Time of Maximum Concentration 2.60 hr (± 1.10 sd)
Elimination Rate Constant 0.049 per hr (± 0.030 sd)
Half-Life 16.33 hr (± 4.53 sd)

Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with normal function (creatinine clearance about 75 mL/min). This percentage excretion may fall as low as 1 to 5%/72 hours in individuals with severe renal insufficiency (creatinine clearance below 10 mL/min). Studies have shown no significant difference in serum half-life of doxycycline (range 18 to 22 hours) in individuals with normal and severely impaired renal function.

Hemodialysis does not alter serum half-life.

Microbiology

Mechanism of Action

Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria. Cross resistance with other tetracyclines is common.

Doxycycline has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section of the package insert.

Gram-Negative Bacteria

Acinetobacter species

Bartonella bacilliformis

Brucella species

Enterobacter aerogenes

Escherichia coli

Francisella tularensis

Haemophilus ducreyi

Haemophilus influenzae

Klebsiella granulomatis

Klebsiella species

Neisseria gonorrhoeae

Shigella species

Vibrio cholerae

Vibrio fetus

Yersinia pestis

Gram-Positive Bacteria

Bacillus anthracis

Streptococcus pneumoniae

Anaerobes

Clostridium species

Fusobacterium fusiforme

Propionibacterium acnes

Other Bacteria

Nocardiae and other aerobic Actinomyces species

Borrelia recurrentis

Chlamydophila psittaci

Chlamydia trachomatis

Mycoplasma pneumoniae

Rickettsiae

Treponema pallidum

Treponema pallidum subspecies pertenue

Ureaplasma urealyticum

Parasites

Balantidium coli

Entamoeba species

Plasmodium falciparum*

* Doxycycline has been found to be active against the asexual erythrocytic forms of Plasmodium falciparum , but not against the gametocytes of P. falciparum. The precise mechanism of action of the drug is not known.

Susceptibility Testing Methods

When available, the clinical microbiology laboratory should provide the results of in vitro susceptibility test results for antimicrobial drugs used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.

Dilution techniques

Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method (broth and/or agar).1,2,4,6,7 The MIC values should be interpreted according to criteria provided in Table 1.

Diffusion techniques

Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standard test method.1,3,4 This procedure uses paper disks impregnated with 30 mcg doxycycline to test the susceptibility of bacteria to doxycycline. The disk diffusion interpretive criteria are provided in Table 1.

Anaerobic Techniques

For anaerobic bacteria, the susceptibility to doxycycline can be determined by a standardized test method.5 The MIC values obtained should be interpreted according to the criteria provided in Table 1.

Table 1: Susceptibility Test Interpretive Criteria for Doxycycline and Tetracycline
*
Organisms susceptible to tetracycline are also considered susceptible to doxycycline. However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxycycline.
The current absence of resistance isolates precludes defining any results other than “Susceptible”. If isolates yielding MIC results other than susceptible, they should be submitted to a reference laboratory for further testing.
Gonococci with 30 mcg tetracycline disk zone diameters of <19 mm usually indicate a plasmid-mediated tetracycline resistant Neisseria gonorrhoeae isolate. Resistance in these strains should be confirmed by a dilution test (MIC ≥ 16 mcg/mL).
Bacteria * Minimal Inhibitory Concentration ( mcg / mL ) Zone Diameter ( mm ) Agar Dilution ( mcg / mL )
S I R S I R S I R
Acinetobacter spp .
Doxycycline ≤4 8 ≥16 ≥13 10 to 12 ≤9
Tetracycline ≤4 8 ≥16 ≥15 12 to 14 ≤11
Anaerobes
Tetracycline ≤4 8 ≥16
Bacillus anthracis
Doxycycline ≤1
Tetracycline ≤1
Brucella species
Doxycycline ≤1
Tetracycline ≤1
Enterobacteriaceae
Doxycycline ≤4 8 ≥16 ≥14 11 to 13 ≤10
Tetracycline ≤4 8 ≥16 ≥15 12 to 14 ≤11
Franciscella tularensis
Doxycycline ≤4
Tetracycline ≤4
Haemophilus influenzae
Tetracycline ≤2 4 ≥8 ≥29 26 to 28 ≤25
Mycoplasma pneumoniae
Tetracycline ≤2
Neisseria gonorrhoeae
Tetracycline ≥38 31 to 37 ≤30 ≤0.25 0.5 to 1 ≥2
Norcardiae and other aerobic Actinomyces species
Doxycycline ≤1 2 to 4 ≥8
Streptococcus pneumoniae
Doxycycline ≤ 0.25 0.5 > 1 > 28 25 to 27 < 24
Tetracycline <1 2 > 4 > 28 25 to 27 < 24
Vibrio cholerae
Doxycycline ≤4 8 ≥16
Tetracycline ≤4 8 ≥16
Yersinia pestis
Doxycycline ≤4 8 ≥16
Tetracycline ≤4 8 ≥16
Ureaplasma urealyticum
Tetracycline ≤1 ≥2

A report of Susceptible (S) indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations at the infection site necessary to inhibit growth of the pathogen. A report of Intermediate (I) indicates that the result should be considered equivocal, and, if the bacteria is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug product is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant (R) indicates that the pathogen is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the infection site; other therapy should be selected.

Quality Control

Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test.1,2,3,4,5,6,7 Standard doxycycline and tetracycline powders should provide the following range of MIC values noted in Table 2. For the diffusion technique using the 30 mcg doxycycline disk the criteria in Table 2 should be achieved.

Table 2: Acceptable Quality Control Ranges for Susceptibility Testing for Doxycycline and Tetracycline
QC Strain Minimal Inhibitory Concentration ( mcg / mL ) Zone Diameter ( mm ) Agar Dilution ( mcg / mL )
Enterococcus faecalis ATCC 29212
Doxycycline 2 to 8
Tetracycline 8 to 32
Escherichia coli ATCC 25922
Doxycycline 0.5 to 2 18 to 24
Tetracycline 0.5 to 2 18 to 25
Eggerthella lenta ATCC 43055
Doxycycline 2 to 16
Haemophilus influenzae ATCC 49247
Tetracycline 4 to 32 14 to 22
Neisseria gonorrhoeae ATCC 49226
Tetracycline 30 to 42 0.25 to 1
Staphylococcus aureus ATCC 25923
Doxycycline 23 to 29
Tetracycline 24 to 30
Staphylococcus aureus ATCC 29213
Doxycycline 0.12 to 0.5
Tetracycline 0.12 to 1
Streptococcus pneumoniae ATCC 49619
Doxycycline 0.015 to 0.12 25 to 34
Tetracycline 0.06 to 0.5 27 to 31
Bacteroides fragilis ATCC 25285
Tetracycline 0.12 to 0.5
Bacteroides thetaiotaomicron ATCC 29741
Doxycycline 2 to 8
Tetracycline 8 to 32
Mycoplasma pneumoniae ATCC 29342
Tetracycline 0.06 to 0.5 0.06 to 0.5
Ureaplasma urealyticum ATCC 33175
Tetracycline ≥ 8
Page 1 of 4 1 2 3 4

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.